Exagen Elects Frank Stokes to Board of Directors
June 18 2021 - 8:29AM
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing
solutions, is proud to announce the company’s stockholders approved
the election of Mr. Frank Stokes as an additional independent
member to its Board of Directors at the Annual Meeting held on June
17, 2021. Mr. Stokes will also serve as Chair of the Audit
Committee.
“We are excited to welcome Mr. Frank Stokes to our dedicated
Board of Directors,” said Ron Rocca, Exagen’s President and Chief
Executive Officer. “Frank brings tremendous capabilities as both a
former investment banker and a current CFO for a public skin care
diagnostic company. His multifaceted experience and knowledge in
the advanced diagnostics and life sciences industry will be
valuable for the next phase of Exagen’s growth.”
"I am honored to join the board of an innovative company with a
successful track record and reputation for enabling providers to
improve care for patients through the differential diagnosis,
prognosis and monitoring of complex autoimmune and
autoimmune-related diseases,” said Mr. Stokes. “Exagen offers a
highly valuable testing portfolio. I look forward to working with
the executive leadership team and board of directors, as the
Company continues to execute on its compelling mission and growth
strategy.”
Mr. Stokes has served as the Chief Financial Officer of Castle
Biosciences, Inc., a skin cancer diagnostics company, since
December 2017. From January 2017 to December 2017, Mr. Stokes
served as Chief Financial Officer of Hammock Pharmaceuticals, a
specialty pharmaceutical company focused on the development and
commercialization of women's health and urology products. From May
2011 to December 2016, Mr. Stokes served as a Managing Director of
Leerink Swann (now SVB Leerink). Mr. Stokes also held positions as
a Managing Director at Robert W. Baird & Co. Incorporated and
Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird
& Co., Mr. Stokes led life sciences, tools and diagnostics
sector investment banking efforts and managed financings and
mergers and acquisitions transactions. Mr. Stokes obtained a
Bachelor of Science in Business Administration, Master of Business
Administration and Doctor of Jurisprudence, all from the University
of North Carolina at Chapel Hill.
About Exagen
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For more information, please visit
www.Exagen.com.
CONTACTS:
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024